Monica Pittiglio

Monica Pittiglio

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
MDMaite Loreto Docampo-Palacios
Maite Loreto Docampo-Palacios
GRGiovanni Ramirez
Giovanni Ramirez
TTTesfay T. Tesfatsion
Tesfay T. Tesfatsion
AOAlex Okhovat
Alex Okhovat
MPMonica Pittiglio
Monica Pittiglio
WCWESTLEY CRUCES
WESTLEY CRUCES
Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure–activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.

3 August 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
MDMaite Loreto Docampo-Palacios
Maite Loreto Docampo-Palacios
GRGiovanni Ramirez
Giovanni Ramirez
TTTesfay Tesfatsion
Tesfay Tesfatsion
AOAlex Okhovat
Alex Okhovat
MPMonica Pittiglio
Monica Pittiglio
WCWESTLEY CRUCES
WESTLEY CRUCES
Natural and non-natural hexahydrocannabinols (HHC) were first described in 1940 by Adam and in late 2021 arose on the drug market in the United States and in some European countries. A background on the discovery, synthesis, and pharmacology studies of hydrogenated and saturated cannabinoids is described. This is harmonized with a summary and comparison of the cannabinoid receptor affinities of various classical, hybrid, and non-classical saturated cannabinoids. A discussion of structure-activity relationships with the four different pharmacophores found in the cannabinoid scaffold is added to this review. According to laboratory studies in vitro, and in several animal species in vivo, HHC is reported to have broadly similar effects to Δ9-tetrahydrocannabinol (Δ9-THC), the main psychoactive substance in cannabis, as demonstrated both in vitro and in several animal species in vivo. However, the effects of HHC treatment have not been studied in humans, and thus a biological profile has not been established.

10 January 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
MDMaite Loreto Docampo-Palacios
Maite Loreto Docampo-Palacios
GRGiovanni Ramirez
Giovanni Ramirez
TTTesfay Tesfatsion
Tesfay Tesfatsion
MPMonica Pittiglio
Monica Pittiglio
KRKyle Ray
Kyle Ray
WCWESTLEY CRUCES
WESTLEY CRUCES
As hemp-based cannabinoids are continuously gaining popularity, synthesis and extraction methods for these compounds are ever-changing. Within the cannabinoid market, hydrogenated derivatives are also gaining popularity at an accelerated rate, with the need for in-depth analysis of these compounds pertinent to increasing the knowledge of cannabis chemistry. Our lab used Schrödinger to dock natural and synthetic cannabinoids in various CB1 and CB2 receptors, PPAR-γ, PAK1, and GPR119 complex including several enzymes, to evaluate the interacting residues within the known binding pockets, comprising the computation of binding energies, predicting ADME characteristics, and evaluating P450 sites of metabolism. The purpose of identifying active residues, sites of metabolism, and ADME characteristics for 40 various cannabinoids is to provide guidance in computer-aided drug design and rationalization in designing and synthesis of analogs.

8 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
MDMaite Loreto Docampo-Palacios
Maite Loreto Docampo-Palacios
GRGiovanni Ramirez
Giovanni Ramirez
TTTesfay Tesfatsion
Tesfay Tesfatsion
MPMonica Pittiglio
Monica Pittiglio
KRKyle Ray
Kyle Ray
WCWESTLEY CRUCES
WESTLEY CRUCES
The surge in the popularity of cannabinoids has led to a proliferation of companies catering to the demand for such products. As the number of suppliers rises, so does the availability of consumable cannabinoid products. While some products undergo testing to meet acceptable standards, many companies opt for minimal testing that overlooks uncommon contaminants potentially harmful during smoking or inhalation. The unregulated cannabinoid market relies on reputable companies to establish standards ensuring the cleanliness of cannabinoid products. Although numerous reports explore the efficacy of cannabinoids, safety remains less extensively documented. Misconceptions about recreational cannabis use and variations in study methodologies, indications, dosing, and administration protocols hinder the overall assessment of the safety of cannabinoid-based medicines. The similarity in retention times and UV absorbance among many cannabinoids adds complexity to distinguishing isomers. Alternative techniques such as LC/MS, GC/MS, and NMR can aid in characterizing cannabinoids. Our study involved testing both high-purity cannabinoids and products from various companies, including crude and distilled THC, HHC, and THCP products which are popular among consumers. These tests were conducted against in-vitro lung cell lines to simulate the absorption of these products during inhalation. Considering the unregulated nature of the markets and the presence of both high-quality and low-quality products, our findings emphasize the importance for companies and consumers to prioritize clean products to remain competitive.

22 October 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
ABAna Barovic
Ana Barovic
MPMonica Pittiglio
Monica Pittiglio
JBJustin Barrett
Justin Barrett
CAChristopher Aretz
Christopher Aretz
TTTesfay Tesfatsion
Tesfay Tesfatsion
WCWESTLEY CRUCES
WESTLEY CRUCES
Novel psychoactive substances (NPS) remain an ongoing challenge for public health, forensic laboratories, and regulatory agencies, especially when they are chemically related to controlled tryptamines but marketed as legal alternatives. In the United States, the Federal Analogue Act (FAA) was intended to restrict such substances; however, regulatory loopholes continue to be exploited. Herein, we present the characterization of a commercially available tablet marketed under the brand name Party Duck, alongside an unlabeled powder provided to our laboratory. Samples were analyzed using nuclear magnetic resonance (NMR) spectroscopy, gas chromatography mass spectrometry (GC/MS), and liquid chromatography mass spectrometry (LC/MS). All materials were identified to contain 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET), a synthetic psychedelic structurally and pharmacologically similar to psilocin. The mean concentration of 4-HO-MET in the tablets was determined to be 2.82 mg/g or 1.45 mg/tablet, while the powder was confirmed qualitatively to contain the same compound. These findings demonstrate that 4-HO-MET is present in commercially available products and emphasizes the importance of rigorous analytical methods for continuous monitoring of tryptamine derivatives in unregulated markets.

10 June 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
GRGiovanni Ramirez
Giovanni Ramirez
TTTesfay Tesfatsion
Tesfay Tesfatsion
MPMonica Pittiglio
Monica Pittiglio
KRKyle Ray
Kyle Ray
AWAndrew Westerkamp
Andrew Westerkamp
WCWESTLEY CRUCES
WESTLEY CRUCES
Cannabinoids, particularly those derived from cannabis, have attracted considerable attention in recent years for their therapeutic potential in treating various diseases and ailments. In this study, we identified cannabinoid byproducts that result from the combustion of cannabidiol (CBD) - henceforth referred to as pyrocannabinoids - and employed molecular docking simulations to investigate their interactions with key protein targets implicated in different physiological processes. Specifically, we focused on peroxisome proliferator-activated receptor gamma (PPAR-γ), p21-activated kinase 1 (PAK1), CB1, CB2, and GPR119 proteins, elucidating the binding modes and affinities of pyrocannabinoid byproducts to these receptors. This investigation was done in collaboration with Real Isolates LLC. Our findings revealed diverse ligand-protein interactions, with some pyrocannabinoids displaying favorable binding energies and stable ligand-protein complexes. However, variations in binding affinities across different proteins underscored the complex pharmacological profiles of the pyrocannabinoids. Furthermore, the prediction of adsorption, distribution, metabolism, excretion and toxicity (ADMET) properties highlighted both promising and concerning aspects of cannabinoid pharmacokinetics, emphasizing the need for thorough preclinical evaluation. Additionally, our investigation into potential metabolic sites using cytochrome P450 enzymes provided insights into cannabinoid metabolites. Overall, our study contributes to the understanding of pyrocannabinoid pharmacology and informs the rational design of pyrocannabinoid-based therapeutics. Further experimental validation is warranted to translate these findings into clinically relevant applications.